These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24010011)

  • 1. Management of Diabetic Nephropathy in the Elderly: Special Considerations.
    Abdel-Rahman EM; Alhamad T; Reeves WB; Awad AS
    J Nephrol Ther; 2012 Oct; 2(5):. PubMed ID: 24010011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.
    Abdel-Rahman EM; Saadulla L; Reeves WB; Awad AS
    J Gen Intern Med; 2012 Apr; 27(4):458-68. PubMed ID: 22005942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and Management of Diabetic Nephropathy in Western Countries.
    Satirapoj B; Adler SG
    Kidney Dis (Basel); 2015 May; 1(1):61-70. PubMed ID: 27536666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.
    Ruilope LM; Segura J
    Clin Ther; 2003 Dec; 25(12):3044-64. PubMed ID: 14749145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on the management of nephropathy in type 2 diabetes.
    Zhao HL; Thomas GN; Leung W; Tomlinson B; Hsu YH; Chan P
    J Chin Med Assoc; 2003 Nov; 66(11):627-36. PubMed ID: 14768849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging therapeutic strategies in diabetic nephropathy.
    Ravera M; Re M; Weiss U; Deferrari L; Deferrari G
    J Nephrol; 2007; 20 Suppl 12():S23-32. PubMed ID: 18050139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of diabetic nephropathy: Recent progress and future perspective.
    Ahmad J
    Diabetes Metab Syndr; 2015; 9(4):343-58. PubMed ID: 25845297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy.
    Ilyas Z; Chaiban JT; Krikorian A
    Rev Endocr Metab Disord; 2017 Mar; 18(1):21-28. PubMed ID: 28289965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel effective drugs for diabetic kidney disease? or not?
    Gentile G; Mastroluca D; Ruggenenti P; Remuzzi G
    Expert Opin Emerg Drugs; 2014 Dec; 19(4):571-601. PubMed ID: 25376947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH; Hovind P
    Curr Hypertens Rep; 2002 Oct; 4(5):387-93. PubMed ID: 12217258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of angiotensin-1 converting enzyme 2 gene (G8790A) polymorphism in patients of type 2 diabetes mellitus with diabetic nephropathy in Pakistani population.
    Younas H; Ijaz T; Choudhry N
    PLoS One; 2022; 17(2):e0264038. PubMed ID: 35176079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Prevalence and Management of Diabetic Nephropathy in Asia.
    Tomino Y; Gohda T
    Kidney Dis (Basel); 2015 May; 1(1):52-60. PubMed ID: 27536665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
    Hughes DB; Britton ML
    Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Renin-Angiotensin-Aldosterone System Inhibition for the Treatment of Diabetic Kidney Disease: Adverse Effects and Unfulfilled Promise.
    El-Haddad B; Reule S; Drawz PE
    Curr Diab Rep; 2015 Oct; 15(10):70. PubMed ID: 26275442
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.